Re:Search Institution Members

152 Results for Members

Members

Researchers at the Faculty of Science and Faculty of Health Sciences of the University of Bamenda pursue...

The Massachusetts General Hospital is a teaching hospital for Harvard University’s medical school and have...

The University of Ghana has a holistic approach to research, innovation and development - focusing on research...

The South African Medical Research Council (SAMRC) has a mandate to improve the health of the country’s...

Researchers at the University of Kansas, and in particular the KU Medical Center, work across a broad range of...

The University of Mauritius focuses on capacity building and instilling community responsibility through its...

159 Results for Collaborations

Collaborations

A LSTM researcher provided a UCSF researcher with stool and plasma samples from Trichuris-infected children from Ecuador. The UCSF researcher compared the amount of specific factors present in infected vs. uninfected samples.

A McGill University researcher provided a UBC researcher with frozen cell extracts of Cryptosporidium infected cells. The UBC researcher used these extracts to identify potential antigens for use in a vaccine.

A McGill University researcher will provide a UBC researcher with frozen cell extracts of T. cruzi infected cells. The UBC researcher will use these extracts to identify potential antigens for use in a vaccine.

PATH and a researcher from McMaster University co-developed a microfluidic diagnostic to detect bacteria in banked milk.

Merck KGaA, Darmstadt, Germany will provide a University of California, San Diego (UCSD) investigator with a targeted library of phosphoinositide-3-kinase (PI3K) inhibitors. The UCSD investigator will screen these inhibitors for activity against the causative agents of Chagas disease, human African trypanosomiasis, and leishmaniasis.

Merck KGaA, Darmstadt, Germany will provide a University of Buea researcher with a subset of highly potent Hsp90 inhibitors to screen against Onchocerca worms, and identify compounds that selectively kill both microfilariae and adult O. volvulus, without adverse effects to Loa loa microfilariae.

170 Results for Assets

Assets

Fenarimol as starting point for SAR investigations aimed at improving activity against T.cruzi and developing compounds suitable for in vivo characterisation. This second release of data contains data sets on the two more advanced fenarimol series, from which two preclinical candidates were identified.
A novel axenic amastigote Leishmania assay was developed and validated that reports only cytocidal molecules. It was used to screen a diversity-oriented synthesis library and two new chemical series with antileishmanial activity were identified. The new axenic assay has a significantly improved translation to the intracellular assay.
The University of Bamako is willing to enter into partnerships with organizations looking to make use of its five sites for clinical trials, which are certified by the Clinical and Laboratory Standards Institute. Its facilities are also certified for hematology and biochemistry, and specialize in malaria drugs and vaccines. The university also has experience with other parasitic diseases including schistosomiasis, onchocerciasis and leishmaniasis. The university can also provide staff for volunteer recruitment, monitoring, clinical care for volunteers, and the possibility for interaction with the community.
A low cost production process for mefloquine hydrochloride has been developped (new method of synthesis). This could significantly reduce the production cost of a combination product such as ASMQ.
Screening commercially available compounds in GNF's nonproprietary libraries identified inhibitors of proliferation of P. falciparum strain 3D7 in human erythrocytes. The dataset contains the structures and screening data for over 5,600 compounds, which were tested in dose response and confirmed to inhibit parasite growth by more than 50% at the highest screening concentration (1.25 or 12.5 uM). Over 3200 compounds of these compounds were available for testing in powder format which allowed for testing at higher concentrations (12.5 uM) using freshly diluted stocks. Activity against the multidrug resistant W2 strain is also available. In addition, we have included data for a human cell cytotoxicity selectivity screen using the Huh7 human hepatocellular carcinoma cell line and deposited an indication of the 'promiscuity' of the hits (the IFI index) in other high-throughput assays at the Genomics Institute of the Novartis Research Foundation. All efforts have been made to ensure data quality and accuracy, but users are reminded that these data carry the usual caveats associated with results from large scale screening.